(CercleFinance.com) – Crossject announced Friday the entry to its supervisory board of Daniel Teper, a pharmaceutical industry executive based in the United States, with the objective of expanding into the American market.
The French company, the originator of a patented needle-free self-injection system, points out that this appointment comes at a ‘key’ moment for the company, that is to say against a background of transition as as a laboratory specialized in pharmacy in the United States.
Crossject hopes that the arrival of the businessman will help it achieve its growth objectives, in particular by contributing to the success of Zeneo, its needle-free self-injection system, across the Atlantic.
Daniel Teper began his career at Novartis headquarters in Basel, where he quickly took on increasing responsibilities in sales, marketing and new product development in the United States.
After returning to Europe, he held a commercial position at Glaxo, before becoming a partner at EuroRSCG Havas Santé, where he advised large pharmaceutical groups in the launch of several drugs.
He currently holds the position of Managing Director at Cytovia Therapeutics.
Thanks to its technology, Crossject aims to become the world leader in self-administered emergency medication (epilepsy, overdose, allergic shock, severe migraine, asthma attack, etc.).